购物车
- 全部删除
- 您的购物车当前为空
ON123300 是一种可透过血脑屏障的多激酶抑制剂,作用于 CDK4、CDK6、Ark5、PDGFRβ、FGFR1、RET 和 Fyn,IC50值为3.9、9.82、5、26、26、9.2和11 nM。它在脑肿瘤中抑制 Akt 磷酸化及激活 Erk。
为众多的药物研发团队赋能,
让新药发现更简单!
ON123300 是一种可透过血脑屏障的多激酶抑制剂,作用于 CDK4、CDK6、Ark5、PDGFRβ、FGFR1、RET 和 Fyn,IC50值为3.9、9.82、5、26、26、9.2和11 nM。它在脑肿瘤中抑制 Akt 磷酸化及激活 Erk。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 343 | 现货 | |
2 mg | ¥ 496 | 现货 | |
5 mg | ¥ 818 | 现货 | |
10 mg | ¥ 1,330 | 现货 | |
25 mg | ¥ 2,290 | 现货 | |
50 mg | ¥ 3,480 | 现货 | |
100 mg | ¥ 5,220 | 现货 | |
500 mg | ¥ 10,600 | 现货 |
产品描述 | ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM). |
靶点活性 | RET:9.2nM, FGFR1:26nM, CDK4:3.9nM, Ark5:5nM, PDGFRβ:26nM, Fyn:11 nM |
激酶实验 | CDK1 kinase activity is tested by the CDK1/cyclin B complex purified from baculovirus to phosphorylate a biotinylated peptide substrate containing the consensus phosphorylation site for histone H1, which is phosphorylated in vivo by CDK1. Inhibition of CDK1 activity is measured by observing a decreased amount of 33P-γ-ATP incorporation into the immobilized substrate in streptavidin-coated 96-well scintillating microplates. CDK1 enzyme is diluted in 50 mM Tris-HCl (pH 8), 10 mM MgCl2, 0.1 mM Na3VO4, 1 mM DTT, 1% DMSO, 0.25 μM peptide, 0.1 μCi per well 33P-γ-ATP, and 5 μM ATP in the presence or absence of various concentrations of JNJ-7706621 and incubated at 30 °C for 1 hour. The reaction is terminated by washing with PBS containing 100 mM EDTA and plates are counted in a scintillation counter. IC50 is determined by Linear regression analysis of the percent inhibition by JNJ-7706621. |
分子量 | 429.52 |
分子式 | C24H27N7O |
CAS No. | 1357470-29-1 |
Smiles | CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1 |
密度 | 1.35 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度信息 | Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: <1 mg/mL (insoluble or slightly soluble) |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容